Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonidine for Obesity-Related Inflammation (MAPLE)
NCT04934228Phase 1Recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Jul 2021
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Clonidine Lauriad in obesity (3 arms), sponsored by University of Kansas Medical Center. Primary endpoints: Circulating blood concentrations of inflammatory markers (e.g., TNF-alpha, IL-6) at 4 weeks, Endothelial cell expression of inflammatory markers at 4 weeks and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
Clonidine Lauriad
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04934228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934228.